We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Cardio Diagnostics Holdings, Inc.
Health Care · Biotechnology
Structural: cardiovascular disease remains the #1 global killer; standard lipid/CRP panels miss ~50% of first-event MI patients, creating demand for next-gen biomarker screening. Epigenetic methylation signatures are reproducible and actionable earlier than genomic SNP panels.
PrecisionCHD fills a genuine diagnostic gap; direct-to-physician commercialization avoids hospital procurement drag; AI/epigenetics narrative could command premium multiple on any revenue inflection; tiny float magnifies any catalyst.
Pre-revenue microcap burning cash with no commercial-scale traction evidence; reimbursement pathway unclear (CPT coverage risk is binary); competing against established players (Quest, LabCorp, Foundation Medicine) with vastly more distribution; dilution risk severe at sub-$10M market cap.
No key levels recorded for this ticker.